Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Angiotensin II receptor blockers in patients with systemic right ventricular dysfunction

Trial Profile

Angiotensin II receptor blockers in patients with systemic right ventricular dysfunction

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2012

At a glance

  • Drugs Valsartan (Primary)
  • Indications Right ventricular dysfunction
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 29 Aug 2012 Results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
    • 02 Feb 2011 Last checked against ISRCTN: Current Controlled Trials.
    • 01 Nov 2010 Rationale and trial design were presented in an article in the American heart journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top